comparemela.com

Latest Breaking News On - Psoriasis area severity index - Page 2 : comparemela.com

Probiotic Supplementation May Serve as Psoriasis Treatment Option, Study Finds

This meta-analysis demonstrates the possibilities for probiotic supplementation, though additional multi-center clinical studies with larger samples may be needed.

Chengdu
Sichuan
China
Xiaoshu-liao
Kebo-wei
Cochrane-library
Dermatology-life-quality-index
Psoriasis-area-severity-index
Chengdu-university
Traditional-chinese-medicine

Psoriasis in Women

Psoriasis takes a higher toll on female patients and may impact pregnancy outcomes

Chapel-hill
North-carolina
United-states
Iran
United-kingdom
Toronto
Ontario
Canada
Denmark
Danish
Iranian
British

Impact of TNFi, IL-17Ai Treatments on Psoriatic Arthritis Biomarkers

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

Denmark
Bispebjerg
Hovedstaden
Frederiksberg
Nordjylland
Marie-skougaard
Parker-institute
Copenhagen-university-hospital-bispebjerg
Parker-institute-marie-skougaard
Psoriasis-area-severity-index
Disease-activity
Psoriatic-arthritis

Guselkumab Outperforms Ustekinumab in Indirect Comparison PsA Analysis

Guselkumab Outperforms Ustekinumab in Indirect Comparison PsA Analysis
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Belgium
Beerse
Region-flamande
Pushpike-thilakarathne
American-college-of-rheumatology
Department-at-janssen-pharmaceutica
American-college
Psoriasis-area-severity-index
Janssen-pharmaceutica

Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

San-diego
California
United-states
Oregon
American
Andrew-blauvelt
American-academy-of-dermatology
Oregon-medical-research-center
American-academy
Psoriasis-area-severity-index
Risankizumab
Skyrizi

vimarsana © 2020. All Rights Reserved.